Report: Vaccine for HPV Is Effective
Washington — Vaccinating teen girls against human papillomavirus, the most common sexually transmitted infection, has helped lead to a 56 percent decline in cases among young women, a U.S. report found.
Among females 14 to 19, the prevalence of certain strains of HPV dropped to about 5 percent in 2007-2010 from about 12 percent in 2003-2006, according to an article released yesterday in The Journal of Infectious Diseases. The shot is 82 percent effective against the virus that can cause cervical cancer if at least one of the three recommended doses is given.
The report suggests inoculation against HPV with vaccines such as Merck & Co.’s Gardasil, approved in 2006, may help achieve a goal of eliminating cervical cancer caused by the virus. The 56 percent drop in the strains of HPV covered by the vaccine from 2003-2006 to 2007-2010 was greater than expected as 34 percent of females ages 14 to 19 report having received at least one dose of the vaccines, the report said.
“These are striking results and they should be a wake-up call that we need to increase vaccinations,” Thomas Frieden, director of the Centers for Disease Control and Prevention, said today in a call with reporters. “It is possible to protect a generation from cancer and we have to do it.”
HPV is the main cause of cervical cancer, according to the CDC, and about 12,000 women get cervical cancer each year. The vaccine needs to be given before a person becomes sexually active to prevent cervical cancer in adults.
Merck’s Gardasil protects against four strains of the virus linked to genital warts and cervical cancer. The vaccine generated more than $1.6 billion in 2012 sales for Whitehouse Station, N.J.-based Merck, the company reported.
Cervarix is an HPV vaccine from London-based GlaxoSmithKline, which had about $428 million in 2012 sales, according to data compiled by Bloomberg.